Novo Holdings has completed its $16.5 billion acquisition of Catalent, the contract drug manufacturer said on Wednesday, days after the companies disclosed that all regulatory conditions to close the deal were fulfilled.

Novo Holdings said that it completed it's $16.5 billion acquisition of Catalent Inc. (NYSE:CTLT). Shortly following the completion of the deal, Novo Nordisk A/S (NVO)  will acquire from Novo Holdings Catalent’s three fill-finish sites located in Anagni,

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

The all-cash deal has involved Novo Holdings acquiring Catalent for $16.5bn, including debt. It will then sell three of Catalent's factories – in Anagni, Italy, Brussels and Bloomington, Indiana – to Novo Nordisk for $11.7bn, enabling the Danish drugmaker to increase production of its obesity and diabetes treatments.

Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge the deal

The $16.5 billion take-private deal can now be completed, and along with it Novo Nordisk’s related acquisition of three Catalent drug manufacturing plants.

Novo Holdings, the controlling shareholder of Novo Nordisk, on Wednesday sealed its $16.5 billion deal for Catalent, as the Danish drugmaker looks to boost supplies of its widely popular weight-loss drug Wegovy.